Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNA92a
- Development stage
- Preclinical
- Lead developer
- Goethe-Universität Frankfurt
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intravenous, Subcutaneous
01
Overview
LNA92a (also known as LNA-92a) is a locked nucleic acid (LNA)-modified antisense oligonucleotide designed to inhibit microRNA-92a (specifically miR-92a-3p). Developed primarily as a research tool and preclinical candidate, LNA92a has been extensively studied in cardiovascular and metabolic diseases. By blocking miR-92a, LNA92a derepresses key target genes such as integrin alpha-5 (ITGA5) and sirtuin-1 (SIRT1), promoting angiogenesis, improving endothelial function, and reducing inflammation. Preclinical studies have demonstrated its therapeutic potential in myocardial infarction, heart failure with preserved ejection fraction (HFpEF), and metabolic dysfunction-associated steatohepatitis (MASH), where it reduces hepatic fibrosis and portal hypertension.
- Other names
- antimiR-92aantimiR92aantimiR 92alocked nucleic acid-modified antisense miR-92amiR-92a inhibitormiR92a inhibitormiR 92a inhibitor
02
Targets
miR-92a (MicroRNA 92a)
Beyond the preview
Go deeper on LNA92a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNA92a.